

Cemiplimab EMPOWER-Lung 1

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Cemiplimab EMPOWER-Lung 1

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: First-line locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC
Experimental Arm: Cemiplimab
Control Arm: Platinum based ChT (Crossover allowed)

